


Flonase (fluticasone propionate) - Drug Summary



Hypersensitivity to any of its ingredients.

CONTRAINDICATIONS

WARNINGS/PRECAUTIONS

May cause local nasal effects (eg, epistaxis, nasal ulceration, Candida infections, nasal septum perforation, impaired wound healing). When localized infections of the nose and pharynx with Candida albicans develop, may need to treat and d/c therapy. Avoid with recent nasal ulcers, nasal surgery, or nasal trauma until healing has occurred. Glaucoma and/or cataracts may develop; closely monitor patients with a change in vision or with a history of increased IOP, glaucoma, and/or cataracts. Hypersensitivity reactions reported; d/c if such reactions occur. May increase susceptibility to infections, caution with active or quiescent TB, systemic fungal, bacterial,

viral or parasitic infections; or ocular herpes simplex. Avoid exposure to chickenpox and measles. D/C slowly if hypercorticism and adrenal suppression occur. Risk of adrenal insufficiency and withdrawal symptoms when replacing systemic corticosteroids with topical corticosteroids. May reduce growth velocity in pediatric patients. Caution with hepatic disease.

ADVERSE REACTIONS

Headache, pharyngitis, epistaxis, nasal burning/irritation, N/V, asthma symptoms, cough.

DRUG INTERACTIONS

Not recommended with strong CYP3A4 inhibitors (eg, ritonavir, clarithromycin, ketoconazole); increased systemic corticosteroid adverse effects may occur.

PREGNANCY AND LACTATION

Category C, caution in nursing.

MECHANISM OF ACTION

Corticosteroid; not established. Shown to have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation.

PHARMACOKINETICS

Absorption: Absolute bioavailability (<2%). **Distribution:** (IV) V_d =4.2L/kg; plasma protein binding (99%). **Metabolism:** Liver via CYP3A4. **Elimination:** (Oral) Urine (<5% metabolites), feces (unchanged and metabolites); (IV) $T_{1/2}$ =7.8 hrs.

ASSESSMENT

Assess for drug hypersensitivity, active or quiescent TB, systemic fungal/bacterial/viral/parasitic infections, ocular herpes simplex, recent nasal ulcers/surgery/trauma, history of increased IOP, glaucoma, or cataracts, hepatic disease, pregnancy/nursing status, and possible drug interactions. Assess if patients have not been immunized or exposed to infections, such as measles or chickenpox.

MONITORING

Monitor for epistaxis, nasal ulceration, nasal septal perforation, impaired wound healing, changes in vision, glaucoma, cataracts, hypersensitivity reactions, infections (eg, chickenpox, measles), hypercorticism, adrenal suppression, hypoadrenalism (in infants born of mothers receiving corticosteroids during pregnancy), and other adverse reactions. Examine periodically for evidence of nasal *Candida* infections. Routinely monitor growth of pediatric patients. Monitor for adrenal insufficiency and withdrawal symptoms when replacing systemic corticosteroid with topical corticosteroid.

PATIENT COUNSELING

Inform of possible local nasal effects, glaucoma, cataracts, hypersensitivity reactions, immunosuppression, and reduced growth velocity (in pediatric patients). Advise patients who have experienced recent nasal ulcers, surgery, or trauma to not use therapy until healing has occurred. Instruct to notify physician if a change in vision develops, and to d/c therapy if hypersensitivity reactions occur. Instruct to avoid exposure to chickenpox or measles; if exposed, advise to consult physician without delay. Instruct to use spray on a regular basis, and not to increase prescribed dosage; advise to contact physician if symptoms do not improve or if condition worsens. Instruct to avoid spraying in eyes and mouth. Advise women to contact physician if they become pregnant.

STORAGE

4-30°C (39-86°F).

Back to top

About Us | Help | Contact Us | Order Books | Report Adverse Events | Privacy Policy | Terms of Service

PDR Information for better health